Biomarkers of prostate cancer sensitivity to the Sendai virus

Белова, А. А.; Сосновцева, А. О.; Lipatova, Anastasiya V.; Njushko, K. M.; Волченко, Н. Н.; Belyakov, M. M.; Судаленко, О. В.; Krasheninnikov, A. A.; Shegai, P. V.; Садритдинова, А. Ф.; Fedorova, Maria S.; Vorobjov, N. V.; Alekseev, B. Ya.; Каприн, А. Д.; Kudryavtseva, Anna V.

doi:10.1134/s0026893317010046

Cited by 5 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Much later, in 1995, several small-scale clinical studies with patients with advanced tumors (stage II and IV) were conducted using SeVM. In some cases, SeVM-based therapy slowed down tumor progression with long-term remission [ 147 , 148 ]. Oncolytic SeVM strain was later sequenced and deposited in Genbank (KP71417) [ 149 ].…”

Section: Oncolytic Viruses In Clinical Trialsmentioning

confidence: 99%

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Malogolovkin

Gasanov

Egorov

et al. 2021

Viruses

View full text Add to dashboard Cite

Recent cancer immunotherapy breakthroughs have fundamentally changed oncology and revived the fading hope for a cancer cure. The immune checkpoint inhibitors (ICI) became an indispensable tool for the treatment of many malignant tumors. Alongside ICI, the application of oncolytic viruses in clinical trials is demonstrating encouraging outcomes. Dozens of combinations of oncolytic viruses with conventional radiotherapy and chemotherapy are widely used or studied, but it seems quite complicated to highlight the most effective combinations. Our review summarizes the results of clinical trials evaluating oncolytic viruses with or without genetic alterations in combination with immune checkpoint blockade, cytokines, antigens and other oncolytic viruses as well. This review is focused on the efficacy and safety of virotherapy and the most promising combinations based on the published clinical data, rather than presenting all oncolytic virus variations, which are discussed in comprehensive literature reviews. We briefly revise the research landscape of oncolytic viruses and discuss future perspectives in virus immunotherapy, in order to provide an insight for novel strategies of cancer treatment.

show abstract

Section: Oncolytic Viruses In Clinical Trialsmentioning

confidence: 99%

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Malogolovkin

Gasanov

Egorov

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…Sensitivity of primary prostatic adenocarcinoma cell lines to Sendai virus inversely correlates with expression levels of TLR3 and TLR7 mRNA. Cell lines with lower expression levels of these TLRs were more sensitive to virus infection …”

Section: Pattern Recognition Receptors For Viral Nucleic Acidsmentioning

confidence: 99%

Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses

Matveeva

Chumakov

2018

Reviews in Medical Virology

View full text Add to dashboard Cite

Increased sensitivity of cancer cells to viruses is a prerequisite for the success of oncolytic virotherapy. One of the major causes of such a phenotype is the disruption of innate antiviral defenses associated with dysfunction of type 1 interferons (IFNs) that permits unlimited replication of viruses in cancer cells. Defects in IFN pathways help cancer progression by providing additional advantages to tumor cells. However, while these defects promote the survival and accelerated proliferation of malignant cells, they facilitate viral replication and thus enhance the efficiency of viral oncolysis. This review describes a broad spectrum of defects in genes that participate in IFN induction and IFN response pathways. Expression levels and/or functional activities of these genes are frequently low or absent in cancer cells, making them sensitive to virus infection. Therefore, certain specific defects in IFN signaling cascades might serve as potential biomarkers to help in identifying individual cancer patients who are likely to benefit from oncolytic virotherapy.

show abstract

“…Being a multifactorial age-related disease, prostate cancer (PC) also depends upon demographic factors, race, and genetic predisposition (Belova et al, 2017). A clear association between older age and prostate cancer is confirmed by the elevation of incidence in men over 60 years of age (Vinjamoori et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer

et al. 2019

View full text Add to dashboard Cite

Older age is one of the main risk factors for cancer development. The incidence of prostate cancer, as a multifactorial disease, also depends upon demographic factors, race, and genetic predisposition. Prostate cancer most frequently occurs in men over 60 years of age, indicating a clear association between older age and disease onset. Carcinogenesis is followed by the deregulation of many genes, and some of these changes could serve as biomarkers for diagnosis, prognosis, prediction of drug therapy efficacy, as well as possible therapeutic targets. We have performed a bioinformatic analysis of a The Cancer Genome Atlas (TCGA) data and RNA-Seq profiling of a Russian patient cohort to reveal prognostic markers of locally advanced lymph node-negative prostate cancer (lymph node-negative LAPC). We also aimed to identify markers of the most common molecular subtype of prostate cancer carrying a fusion transcript TMPRSS2-ERG . We have found several genes that were differently expressed between the favorable and unfavorable prognosis groups and involved in the enriched KEGG pathways based on the TCGA ( B4GALNT4 , PTK6 , and CHAT ) and Russian patient cohort data ( AKR1C1 and AKR1C3 ). Additionally, we revealed such genes for the TMPRSS2-ERG prostate cancer molecular subtype ( B4GALNT4 , ASRGL1 , MYBPC1 , RGS11 , SLC6A14 , GALNT13 , and ST6GALNAC1 ). Obtained results contribute to a better understanding of the molecular mechanisms behind prostate cancer progression and could be used for further development of the LAPC prognosis marker panel.

show abstract

Biomarkers of prostate cancer sensitivity to the Sendai virus

Cited by 5 publications

References 32 publications

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses

Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer

Contact Info

Product

Resources

About